The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

Thursday, April 27, 2017

President's Message - April 2017

 Dear Colleagues,

The Society for Immunotherapy of Cancer (SITC) on Monday, May 1 will launch SITC Cancer Immunotherapy connectED, its new online education tool for the greater cancer immunotherapy field. This education portal, part of SITC Cancer Immunotherapy CONNECT, provides educational resources and activities regarding current advances in cancer immunotherapy organized by stakeholder groups (patients, clinicians and researchers).

With the recent explosion of information related to cancer immunotherapy, there is a critical need for an unbiased educational resource destination where everyone can find the information they need, when they need it. SITC connectED will shape how we learn about cancer immunotherapy.

Utilizing a personalized learning system, SITC connectED identifies and delivers resources customized to each individual user. This portal highlights recent advances in the cancer immunotherapy field by providing educational activities using content from SITC and partner educational programs. SITC connectED bridges knowledge gaps by providing online educational opportunities in a convenient and easy to use platform.

Through SITC connectED, clinicians and patients can stay up-to-date on the most novel clinical applications of immunotherapy. Educational materials from live events will also be featured, allowing users to stay at the forefront of research in the immunotherapy field.

SITC connectED provides opportunities for medical professionals to earn continuing education credits (CME, CNE and CPE) and apply new concepts to clinical scenarios through engaging practice activities. Users will be able to utilize robust communication tools to share and collaborate with others in SITC CONNECT communities.

SITC connectED curates a variety of learning activities, including online classes, videos and webinars from world-renowned leaders in the field of cancer immunotherapy. This education portal will also provide opportunities for patients, caregivers and advocates to learn new information about the use of cancer immunotherapy to treat specific disease states.

Watch for an email on Monday providing a link to SITC connectED. I implore you all to experience this innovative learning portal.

Best wishes,











Lisa H. Butterfield, PhD

SITC President